PPARG and fetal growth restriction: In an attempt to further endorse their assertion, the same study group administered the PPARγ antagonist T0070907 to healthy pregnant rats, and determined that the inhibition of PPARγ-associated pathways resulted in hypertension, intrauterine growth restriction, proteinuria, vascular dysfunction, as well as elevated platelet aggregation [110].